Co-Authors
This is a "connection" page, showing publications co-authored by Wenling Wang and Baoying Huang.
Connection Strength
0.955
-
Profiles of SARS-CoV-2 RNA and Antibodies in Inpatients with COVID-19 not Related with Clinical Manifestation: A Single Centre Study. Virol Sin. 2021 10; 36(5):1088-1092.
Score: 0.060
-
A core-shell structured COVID-19 mRNA vaccine with favorable biodistribution pattern and promising immunity. Signal Transduct Target Ther. 2021 05 31; 6(1):213.
Score: 0.059
-
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect Dis. 2021 01; 21(1):39-51.
Score: 0.057
-
Development and effectiveness of pseudotyped SARS-CoV-2 system as determined by neutralizing efficiency and entry inhibition test in vitro. Biosaf Health. 2020 Dec; 2(4):226-231.
Score: 0.056
-
Morphogenesis and cytopathic effect of SARS-CoV-2 infection in human airway epithelial cells. Nat Commun. 2020 08 06; 11(1):3910.
Score: 0.056
-
Lack of antibody-mediated cross-protection between SARS-CoV-2 and SARS-CoV infections. EBioMedicine. 2020 Aug; 58:102890.
Score: 0.056
-
Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2. Cell. 2020 08 06; 182(3):713-721.e9.
Score: 0.055
-
The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice. Nature. 2020 07; 583(7818):830-833.
Score: 0.055
-
Age-related rhesus macaque models of COVID-19. Animal Model Exp Med. 2020 Mar; 3(1):93-97.
Score: 0.055
-
Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020 02 22; 395(10224):565-574.
Score: 0.054
-
A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020 02 20; 382(8):727-733.
Score: 0.054
-
High-Throughput Screening and Identification of Potent Broad-Spectrum Inhibitors of Coronaviruses. J Virol. 2019 06 15; 93(12).
Score: 0.052
-
Humoral and cellular immunity against both ZIKV and poxvirus is elicited by a two-dose regimen using DNA and non-replicating vaccinia virus-based vaccine candidates. Vaccine. 2019 04 03; 37(15):2122-2130.
Score: 0.051
-
Significant Spike-Specific IgG and Neutralizing Antibodies in Mice Induced by a Novel Chimeric Virus-Like Particle Vaccine Candidate for Middle East Respiratory Syndrome Coronavirus. Virol Sin. 2018 Oct; 33(5):453-455.
Score: 0.050
-
Ultrapotent Human Neutralizing Antibody Repertoires Against Middle East Respiratory Syndrome Coronavirus From a Recovered Patient. J Infect Dis. 2018 09 08; 218(8):1249-1260.
Score: 0.049
-
Enhanced protection in mice induced by immunization with inactivated whole viruses compare to spike protein of middle east respiratory syndrome coronavirus. Emerg Microbes Infect. 2018 Apr 04; 7(1):60.
Score: 0.048
-
A novel neutralizing monoclonal antibody targeting the N-terminal domain of the MERS-CoV spike protein. Emerg Microbes Infect. 2017 Jun 28; 6(6):e60.
Score: 0.045
-
A novel neutralizing monoclonal antibody targeting the N-terminal domain of the MERS-CoV spike protein. Emerg Microbes Infect. 2017 May 24; 6(5):e37.
Score: 0.045